Autumn 2014 Workshop: Cognitive and Functional Assessment in Clinical Trials of Alzheimer’s Disease and Its Precursors: Readying for Short-Term and Long Term Clinical Trial Needs
Chairs: Holly Posner, MD; Philip Harvey, PhD
The goals of this working group continue to be further understanding the challenges in assessing for meaningful improvement or decrement in cognition and / or function during the 6 month to 2 year period of a typical clinical trial of AD and its precursors. At this meeting we will also seek to hear from new sources about assessments that are currently in development. And, to bring in the perspective of Regulators and Payers as well as of a Clinical Trial vs an assessment for a physician evaluating a patient diagnostically.